PERSONALITY AND CANCER: DIFFERENCES IN THE CLINICAL AND PSYCHOLOGICAL CHARACTERISTICS OF THE PATIENT'S PERSONALITY AT HIGH AND LOW RATES OF TUMOR GROWTH

In this paper are presented the results and comparative analysis of the clinical and psychological research for the patient's personality with prostate cancer with high and low growth rate of the tumor. It was revealed that the nature of the oncological process does not depend on the perception by the patients of the impact of a traumatic event, in which the disease acts. For patients with a high tumor growth rate, the most characteristic are pliability, credulity, subordination (r = 0,887, p

Download Full-text

Abstract 4571: Autologous TARP peptide vaccination is associated with slowing in PSA velocity and a decrease in tumor growth rate in patients with Stage D0 prostate cancer.

10.1158/1538-7445.am2013-4571 ◽

2013 ◽

Author(s):

Lauren V. Wood ◽

William L. Dahut ◽

Antonio Fojo ◽

James L. Gulley ◽

Ravi Madan ◽

...

Keyword(s):

Prostate Cancer ◽

Growth Rate ◽

Tumor Growth ◽

Tumor Growth Rate ◽

Peptide Vaccination ◽

Psa Velocity

Download Full-text

LB1598 The impact of tumor growth rate on survival of acral melanoma

Journal of Investigative Dermatology ◽

10.1016/j.jid.2018.06.137 ◽

2018 ◽

Vol 138 (9) ◽

pp. B22

Author(s):

J. Ohn ◽

G. Jo ◽

S. Cho ◽

J. Mun

Keyword(s):

Growth Rate ◽

Tumor Growth ◽

Tumor Growth Rate ◽

Acral Melanoma ◽

The Impact

Download Full-text

Tumor Growth Rate Decline Despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough

Cancers ◽

10.3390/cancers13143492 ◽

2021 ◽

Vol 13 (14) ◽

pp. 3492

Author(s):

Veronica Mollica ◽

Stefano Brocchi ◽

Filippo Gustavo Dall’Olio ◽

Laura Marcolin ◽

Alexandro Paccapelo ◽

...

Keyword(s):

Growth Rate ◽

Tumor Growth ◽

Tumor Regression ◽

Evaluation Criteria ◽

Response To Treatment ◽

Tumor Growth Rate ◽

Lower Velocity ◽

Treatment Beyond Progression ◽

The Impact ◽

Kinetics Of

Treatment response is usually assessed by the response evaluation criteria in solid tumors (RECIST). These criteria may not be adequate to evaluate the response to immunotherapy, considering the peculiar patterns of response reported with this therapy. With the advent of immunotherapy these criteria have been modified to include the evaluation of the peculiar responses seen with this type of therapy (iRECIST criteria), including pseudoprogressions and hyperprogressions. Tumor growth rate (TGR) is a dynamic evaluation that takes into account the kinetics of response to treatment and may help catch the real efficacy of an immunotherapy approach. We performed a retrospective monocentric study to explore the impact of TGR change after nivolumab administration as the second or later line of treatment in patients with metastatic renal cell carcinoma (RCC). We evaluated 27 patients, divided into three categories: Disease control (DC) if there was no PD; lower velocity PD (LvPD) if disease progressed but the TGR at second assessment (TGR2) was lower than the TGR at first assessment (TGR1); higher velocity PD (HvPD) if TGR2 was higher than TGR1. The median OS for the DC group was 11.0 months (95% CI 5.0–17.0) (reference) vs. (not reached) NR (95% CI NR-NR) for LvPD (HR 0.27; 95% CI 0.06–1.30; p 0.102) vs. NR (95% CI NR–NR) for HvPD (HR 0.23; 95% CI 0.06–0.88; p 0.032). There was no difference between LvPD and DC (HR 1.21; 95% CI 0.20–7.28; p 0.838). In patients with metastatic RCC, the second or later line of nivolumab treatment may lead to a deceleration in TGR resulting in an improved survival outcome similar to that observed in patients experiencing tumor regression. In this subgroup, especially in the presence of a clinical benefit, continuing the treatment beyond progression can be recommended.

Download Full-text

Tumor growth characteristics of the Walker 256 AR tumor, a regressive variant of the rat Walker 256 A tumor

Brazilian Archives of Biology and Technology ◽

10.1590/s1516-89132010000500014 ◽

2010 ◽

Vol 53 (5) ◽

pp. 1101-1108 ◽

Cited By ~ 2

Author(s):

Fernando Guimarães ◽

Alessandra Soares Schanoski ◽

Tereza Cristina Samico Cavalcanti ◽

Priscila Bianchi Juliano ◽

Ana Neuza Viera-Matos ◽

...

Keyword(s):

Growth Rate ◽

Tumor Growth ◽

Wistar Rats ◽

Tumor Regression ◽

Growth Characteristics ◽

Tumor Growth Rate ◽

Continuous Growth ◽

Tumor Bearing ◽

Walker 256 ◽

Complete Tumor

The present study aimed at characterizing the subcutaneous development of the Walker 256 (W256) AR tumor, a regressive variant of the rat W256 A tumor. Wistar rats were injected subcutaneously with 4x10(6) W256 A or W256 AR tumor cells. The development of tumors was evaluated daily by percutaneous measurements. None of the W256 A tumors (n=20) regressed, but 62% of the W256 AR tumor-bearing rats (n=21) underwent complete tumor regression within 35 days. Continuous growth of AR tumors was characterized by an increase of the tumor growth rate from day 12, which reached values above 1.0 g/day, and were significantly higher (p<0.05) than those of the regressive AR tumors. Immunosuppression by irradiation before subcutaneous injection of AR cells completely abrogated tumor regression and was associated with severe metastatic dissemination. Daily evaluation of the tumor growth rate enabled the discrimination, in advance, between continuously growing tumors and those that regressed later on.

Download Full-text

Targeted Treatment of Experimental Spinal Cord Glioma With Dual Gene-Engineered Human Neural Stem Cells

Neurosurgery ◽

10.1227/neu.0000000000001174 ◽

2015 ◽

Vol 79 (3) ◽

pp. 481-491 ◽

Cited By ~ 11

Author(s):

Alexander E. Ropper ◽

Xiang Zeng ◽

Hariprakash Haragopal ◽

Jamie E. Anderson ◽

Zaid Aljuboori ◽

...

Keyword(s):

Spinal Cord ◽

Stem Cells ◽

Growth Rate ◽

Neural Stem Cells ◽

Tumor Growth ◽

Rat Model ◽

Weight Bearing ◽

Tumor Growth Rate ◽

Intramedullary Spinal Cord ◽

Human Neural Stem Cells

Abstract BACKGROUND There are currently no satisfactory treatments or experimental models showing autonomic dysfunction for intramedullary spinal cord gliomas (ISCG). OBJECTIVE To develop a rat model of ISCG and investigate whether genetically engineered human neural stem cells (F3.hNSCs) could be developed into effective therapies for ISCG. METHODS Immunodeficient/Rowett Nude rats received C6 implantation of G55 human glioblastoma cells (10K/each). F3.hNSCs engineered to express either cytosine deaminase gene only (i.e., F3.CD) or dual genes of CD and thymidine kinase (i.e., F3.CD-TK) converted benign 5-fluorocytosine and ganciclovir into oncolytic 5-fluorouracil and ganciclovir-triphosphate, respectively. ISCG rats received injection of F3.CD-TK, F3.CD, or F3.CD-TK debris near the tumor epicenter 7 days after G55 seeding, followed with 5-FC (500 mg/kg/5 mL) and ganciclovir administrations (25 mg/kg/1 mL/day × 5/each repeat, intraperitoneal injection). Per humane standards for animals, loss of weight-bearing stepping in the hindlimb was used to determine post-tumor survival. Also evaluated were autonomic functions and tumor growth rate in vivo. RESULTS ISCG rats with F3.CD-TK treatment survived significantly longer (37.5 ± 4.78 days) than those receiving F3.CD (21.5 ± 1.75 days) or F3.CD-TK debris (19.3 ± 0.85 days; n = 4/group; P <.05, median rank test), with significantly improved autonomic function and reduced tumor growth rate. F3.DC-TK cells migrated diffusively into ISCG clusters to mediate oncolytic effect. CONCLUSION Dual gene-engineered human neural stem cell regimen markedly prolonged survival in a rat model that emulates somatomotor and autonomic dysfunctions of human cervical ISCG. F3.CD-TK may provide a novel approach to treating clinical ISCG.

Download Full-text